Telos Capital Management Inc. Buys 1,495 Shares of Johnson & Johnson (JNJ)

Telos Capital Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,036 shares of the company’s stock after acquiring an additional 1,495 shares during the quarter. Telos Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,038,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Narwhal Capital Management lifted its holdings in shares of Johnson & Johnson by 2.5% in the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock valued at $4,965,000 after buying an additional 1,010 shares during the period. TT International lifted its holdings in shares of Johnson & Johnson by 254.1% in the 1st quarter. TT International now owns 136,518 shares of the company’s stock valued at $15,930,000 after buying an additional 97,969 shares during the period. Eagle Global Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.6% in the 1st quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock valued at $9,927,000 after buying an additional 1,221 shares during the period. Chilton Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 23.6% in the 1st quarter. Chilton Capital Management LLC now owns 95,055 shares of the company’s stock valued at $12,181,000 after buying an additional 18,122 shares during the period. Finally, LPL Financial LLC lifted its holdings in shares of Johnson & Johnson by 9.7% in the 1st quarter. LPL Financial LLC now owns 957,508 shares of the company’s stock valued at $122,705,000 after buying an additional 84,855 shares during the period. 66.70% of the stock is owned by institutional investors.

Several research firms have recently commented on JNJ. Citigroup raised their price target on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Credit Suisse Group raised their price target on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Raymond James raised their price target on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $142.54.

In related news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.

Shares of JNJ stock opened at $140.68 on Friday. The firm has a market cap of $375.58 billion, a P/E ratio of 19.27, a PEG ratio of 2.19 and a beta of 0.58. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. Johnson & Johnson’s revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply